Table 2.
Visual field parameters at baseline and after 3 months of treatment.
| Baseline MD (dB) | Month 3 MD (dB) | p Value | Baseline VFI (%) | Month 3 VFI (%) | p Value | |
|---|---|---|---|---|---|---|
| Global (mean ± SD) |
−8.96 ± 3.91 | −8.42 ± 4.29 | 0.025 | 77.47 ± 12.83 | 78.52 ± 13.94 | 0.096 |
| Vitamin C (mean ± SD) |
−8.46 ± 3.70 | −8.32 ± 3.87 | 0.727 | 78.35 ± 12.97 | 78.53 ± 13.24 | 0.871 |
| DHA (mean ± SD) |
−9.08 ± 4.07 | −8.86 ± 5.07 | 0.685 | 78.13 ± 12.83 | 77.56 ± 15.72 | 0.719 |
| Citicoline (mean ± SD) | −8.74 ± 3.70 | −8.71 ± 4.17 | 0.957 | 78.50 ± 12.46 | 78.90 ± 13.16 | 0.687 |
| DHA + Citicoline (mean ± SD) |
−9.52 ± 4.36 | −7.85 ± 4.36 | 0.001 | 75.15 ± 13.76 | 78.90 ± 14.82 | 0.008 |
MD, mean defect of visual field; dB, decibels; VFI, visual field index; SD, standard deviation; DHA, docosahexaenoic acid.